DRUG NEWS

2021/07/08

Launched by Sun Pharma in USA for plaque psoriasis

Sun Pharma reported on 23 October 2018 the launch in the
USA of tildrakizumab (ILUMYA) as a therapy for moderate-tosevere
chronic plaque psoriasis in adults. Tildrakizumab, an
anti-IL-23p19 monoclonal antibody, is approved in the EU and
Australia for this indication. The antibody is under phase II/
III evaluation for psoriatic arthritis, ankylosing spondylitis and
axial spondyloarthritis.